ARDS is a life-threatening condition causing widespread capillary leakage and inflammation of the lungs. Breathing becomes difficult and oxygen cannot get into the body. Treatment options for ARDS are limited beyond mechanical ventilation and approximately 40 percent of ARDS patients do not survive. Globally, ARDS affects over 3 million people a year. In the U.S., approximately 240,000 individuals suffer from ARDS annually.
ARDS can be caused by a variety of insults to the lungs including bacterial and viral pneumonia, sepsis, smoke inhalation, aspiration, and, most recently, the COVID-19 virus. These conditions cause the movement of inflammatory cells, including white blood cells (e.g. neutrophils), from the tissue and blood stream into the lung. Once in the lung, these cells release pro-inflammatory molecules called cytokines; this “cytokine storm” leads to ARDS.
Activated MARCKS Protein is critical for inflammatory cells to move to the injured lung. BIO-11006 inhibits activation of MARCKS Protein to reduce the influx of inflammatory cells into the lung and reverse ARDS.